Doctors reveal hidden danger for some Ozempic, Wegovy users with brain disorders

This post was originally published on this site.

Neurologists are warning that popular weight-loss medications could have severe negative effects on neurodegenerative conditionslike ALS.

Jinsy Andrews, MD, a neurologist and director of NYU Langone’s ALS Center, says the very mechanism that makes these drugs popular —rapid weight loss— can go against the biological needs of patients with neuromuscular disorders.

GLP-1 agonists have shown to be highly effective at managing diabetes and obesity, which are major health concerns across the population.However, the doctor emphasized that the clinical rules shift when dealing with amyotrophic lateral sclerosis (ALS).

DR OZ LINKS OBESITY TO CHRONIC DISEASE SURGE, SAYS GLP-1S CAN ‘JUMPSTART’ BETTER HEALTH

In addition to mitigating some of the inflammation related to obesity anddiabetes, GLP-1 medications have been linked to other protective effects.

The therapies have been helpful in reducing cardiovascular disease, stroke risk, liver disease and addiction, according to Andrews.

Woman holds Ozempic pen while standing on a scale.

Neurologists are warning that the rapid weight loss caused by popular GLP-1 medications can severely worsen neurodegenerative conditions like ALS.(iStock)

However, when it comes to an incurable neurodegenerative disease, losing weight and body fat can accelerate a patient’sphysical decline.

For an ALS patient, losing weight can cause the condition to progress faster, Andrews said, because the disease’s unique traits make it dangerous to be in a caloric deficit.

BIG MEDICARE CHANGE SLASHES WEIGHT-LOSS DRUG COSTS FOR ELIGIBLE SENIORS

In fact, standardclinical careguidelines for ALS often recommend that patients actively maintain or even gain weight to help preserve their remaining nerve and muscle function.

While GLP-1s effectively treat obesity and cardiovascular risks in the general public, those same afflictions have been shown to slow ALS progression.(iStock)

“In certain conditions where hypermetabolism is something that negatively affects the disease […] losing weight actually makes the disease worse and move faster,�.

“So, in the setting of a person with ALS — whether they have diabetes or not — using GLP-1s may actually worsen the disease and make for a rapid progression.”

Ozempic injection pen on a white background.

A peer-reviewed case study revealed that an ALS patient experienced a massive, 10-fold acceleration in physical deterioration after starting semaglutide.(iStock)

In a 2025 case report published in the medical journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, a 52-year-old ALS patient wasprescribed semaglutideto treat her type 2 diabetes.

Prior to starting the medication, her physical functions were declining at a predictable rate on the standard ALS rating scale.

According to the case report, the patient lost 25 pounds in three months.At the same time, she experienced a sudden, dramatic shift in her disease trajectory, with symptoms worsening significantly.

“GLP-1s may actually worsen the disease and make for a rapid progression.”
Read More → Could flesh-eating screwworms end up in your beef?USDA reveals risk level

Once the semaglutide was discontinued at the advice of medical professionals, the patient’s rapid physical decline stabilized.

onelink.me/xLDS?pid=AppArticleLink&af_web_dp=https%3A%2F%2Fwww.

Andrews pointed out that this published documentation, alongsideretrospective cohort dataof ALS patients with diabetes, provides growing evidence that clinicians must be careful and thoughtful about who they treat with GLP-1 receptor agonists.

While weight-loss medications offer significant benefits for many patients, experts say maintaining body weight and muscle mass remains an important consideration for people with neurodegenerative diseases.

Healthcare providers should be highly cautious and context-aware when prescribing GLP-1 receptor agonists to patients with underlying neurodegenerative diseases, a neurologist cautioned.(iStock)

“Patient safety is of utmost importance to Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously,�

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

“It’s important to note that ALS and other neurodegenerative diseases are not listed adverse reactions or warnings and precautions in the prescribing information for our semaglutide products, including Ozempic or Wegovy,” he added.

Khloe Quill is a

Apple AirDrop, Android Quick Share flaws put phones at risk

African growth boom follows Trump push to replace aid with trade